Nature Reviews Rheumatology, Published online: 06 November 2026; doi:10.1038/s41584-026-01452-9 Immune checkpoint inhibitor-associated inflammatory arthritis is the most common rheumatic immune-related adverse event. In this Review, the authors discuss current insights into the pathogenesis, clinical presentations and management of immune checkpoint inhibitor-associated inflammatory arthritis, underscoring its distinct biology and therapeutic considerations.
Carrie Ye, David F. L. Liew, Shahin Jamal. Immune checkpoint inhibitor-associated inflammatory arthritis. // Nature Reviews Rheumatology. – 2026. – DOI: 10.1038/s41584-026-01452-9. – URL: https://www.nature.com/articles/s41584-026-01452-9
Carrie Ye, David F. L. Liew, & Shahin Jamal (2026). Immune checkpoint inhibitor-associated inflammatory arthritis. Nature Reviews Rheumatology. https://doi.org/10.1038/s41584-026-01452-9
Carrie Ye, et al. “Immune checkpoint inhibitor-associated inflammatory arthritis.” Nature Reviews Rheumatology, 2026. doi:10.1038/s41584-026-01452-9.
@article{Ye2026,
title = {Immune checkpoint inhibitor-associated inflammatory arthritis},
author = {Ye, Carrie and Liew, David F. L. and Jamal, Shahin},
journal = {Nature Reviews Rheumatology},
year = {2026},
doi = {10.1038/s41584-026-01452-9},
url = {https://www.nature.com/articles/s41584-026-01452-9}
}